Cargando…
Fibroblast Growth Factor 19 Improves LPS-Induced Lipid Disorder and Organ Injury by Regulating Metabolomic Characteristics in Mice
Sepsis is extremely heterogeneous pathology characterized by complex metabolic changes. Fibroblast growth factor 19 (FGF19) is a well-known intestine-derived inhibitor of bile acid biosynthesis. However, it is largely unknown about the roles of FGF19 in improving sepsis-associated metabolic disorder...
Autores principales: | Liu, Tiantian, Tang, Xiaomeng, Cui, Yun, Xiong, Xi, Xu, Yaya, Hu, Shaohua, Feng, Shuyun, Shao, Lujing, Ren, Yuqian, Miao, Huijie, Zhang, Hong, Zhu, Xiaodong, Zhang, Yucai, Wang, Chunxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279090/ https://www.ncbi.nlm.nih.gov/pubmed/35847588 http://dx.doi.org/10.1155/2022/9673512 |
Ejemplares similares
-
IL-22 ameliorates LPS-induced acute liver injury by autophagy activation through ATF4-ATG7 signaling
por: Shao, Lujing, et al.
Publicado: (2020) -
Serum proteome‐wide identified ATP citrate lyase as a novel informative diagnostic and prognostic biomarker in pediatric sepsis: A pilot study
por: Wang, Chunxia, et al.
Publicado: (2020) -
Apolipoprotein A-V Is a Novel Diagnostic and Prognostic Predictor in Pediatric Patients with Sepsis: A Prospective Pilot Study in PICU
por: Wang, Chunxia, et al.
Publicado: (2020) -
Continuous renal replacement therapy attenuates polymorphonuclear myeloid-derived suppressor cell expansion in pediatric severe sepsis
por: Feng, Shuyun, et al.
Publicado: (2022) -
The novel biomarkers for assessing clinical benefits of continuous renal replacement therapy in pediatric sepsis: a pilot study
por: Cui, Yun, et al.
Publicado: (2023)